Pfizer Pays Out On Rituximab Biosimilar

Ruxience Launched In Both US And Japan

 
• By Dean Rudge

Agreements signed between Wyeth and Trubion Pharmaceuticals more than a decade ago have led to Pfizer making royalty payments on its rituximab biosimilar, Ruxience, to Aptevo Therapeutics.

DollarsGraph
Pfizer is due to make its first payment in the coming days • Source: Shutterstock

More from Biosimilars

More from Products